New Data from Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving ... MarketWatch (press release) MINNEAPOLIS & BOSTON, May 11, 2012 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart Failure Trial) trial demonstrating that ... |
